Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation

被引：11

作者：

Kanda, Y ^{[1
]}

Chiba, S ^{[1
]}

Tanaka, Y ^{[1
]}

Kami, M ^{[1
]}

Saito, T ^{[1
]}

Izutsu, K ^{[1
]}

Asai, T ^{[1
]}

Yuji, K ^{[1
]}

Ogawa, S ^{[1
]}

Honda, H ^{[1
]}

Mitani, K ^{[1
]}

Usuki, K ^{[1
]}

Urabe, A ^{[1
]}

Shirakawa, K ^{[1
]}

Yatomi, T ^{[1
]}

Nakamura, N ^{[1
]}

Yazaki, Y ^{[1
]}

Hirai, H ^{[1
]}

机构：

[1] Univ Tokyo, Fac Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, Tokyo 113, Japan

来源：

LEUKEMIA & LYMPHOMA | 1999年 / 34卷 / 5-6期

关键词：

lymphoma; Fas; soluble Fas ligand; B cell; PBSCT; non-Hodgkin's lymphoma;

D O I：

10.3109/10428199909058494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fas-ligand (FasL) is a member of the tumor necrosis factor family and transmits apoptotic cell death signal by binding to its receptor, Fas. Fast is expressed on the cell surface of activated T-cell and natural killer (NK) cell. It has been shown that the Fast can be released from the cell surface by metalloproteinase. The serum soluble Fast (sFasL) is increased in some patients with NK cell lymphoma/large granular lymphocytic leukemia. We have recently seen a patient with recurrent B-cell lymphoma accompanied with an increased serum sFasL level after autologous peripheral blood stem cell transplantation. The sFasL was markedly decreased with the tumor regression induced by the chemotherapy. We present here the first case of an elevated serum sFasL level associated with B-cell lineage malignancy and discuss the possible clinical value of sFasL.

引用

页码：625 / 628

页数：4

共 8 条

[1] Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].

Hahne, M ;

Rimoldi, D ;

Schroter, M ;

Romero, P ;

Schreier, M ;

French, LE ;

Schneider, P ;

Bornand, T ;

Fontana, A ;

Lienard, D ;

Cerottini, JC ;

Tschopp, J .

SCIENCE, 1996, 274 (5291) :1363-1366

[2] Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease [J].

Kanda, Y ;

Tanaka, Y ;

Shirakawa, K ;

Yatomi, T ;

Nakamura, N ;

Kami, M ;

Saito, T ;

Izutsu, K ;

Asai, T ;

Yuji, K ;

Ogawa, S ;

Honda, H ;

Mitani, K ;

Chiba, S ;

Yazaki, Y ;

Hirai, H .

BONE MARROW TRANSPLANTATION, 1998, 22 (08) :751-754

[3] METALLOPROTEINASE-MEDIATED RELEASE OF HUMAN FAS LIGAND [J].

KAYAGAKI, N ;

KAWASAKI, A ;

EBATA, T ;

OHMOTO, H ;

IKEDA, S ;

INOUE, S ;

YOSHINO, K ;

OKUMURA, K ;

YAGITA, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06) :1777-1783

[4] THE FAS DEATH FACTOR [J].

NAGATA, S ;

GOLSTEIN, P .

SCIENCE, 1995, 267 (5203) :1449-1456

[5] An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand [J].

Sato, K ;

Kimura, F ;

Nakamura, Y ;

Murakami, H ;

Yoshida, M ;

Tanaka, M ;

Nagata, S ;

Kanatani, Y ;

Wakimoto, N ;

Nagata, N ;

Motoyoshi, K .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 94 (02) :379-382

[6] Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? [J].

Strand, S ;

Hofmann, WJ ;

Hug, H ;

Muller, M ;

Otto, G ;

Strand, D ;

Mariani, SM ;

Stremmel, W ;

Krammer, PH ;

Galle, PR .

NATURE MEDICINE, 1996, 2 (12) :1361-1366

[7] Downregulation of Fas ligand by shedding [J].

Tanaka, M ;

Itai, T ;

Adachi, M ;

Nagata, S .

NATURE MEDICINE, 1998, 4 (01) :31-36

[8] Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis [J].

Xerri, L ;

Devilard, E ;

Hassoun, J ;

Haddad, P ;

Birg, F .

LEUKEMIA, 1997, 11 (11) :1868-1877

← 1 →